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Summary
Background Findings from observational studies have suggested a delay in nursing home placement with dementia drug 
treatment, but fi ndings from a previous randomised trial of patients with mild-to-moderate Alzheimer’s disease showed 
no eff ect. We investigated the eff ects of continuation or discontinuation of donepezil and starting of memantine on 
subsequent nursing home placement in patients with moderate-to-severe Alzheimer’s disease.
Methods In the randomised, double-blind, placebo-controlled Donepezil and Memantine in Moderate to Severe 
Alzheimer’s Disease (DOMINO-AD) trial, community-living patients with moderate-to-severe Alzheimer’s disease (who 
had been prescribed donepezil continuously for at least 3 months at a dose of 10 mg for at least the previous 6 weeks and 
had a score of between 5 and 13 on the Standardised Mini-Mental State Examination) were recruited from 15 secondary 
care memory centres in England and Scotland and randomly allocated to continue donepezil 10 mg per day without 
memantine, discontinue donepezil without memantine, discontinue donepezil and start memantine 20 mg per day, or 
continue donepezil 10 mg per day and start memantine 20 mg per day, for 52 weeks. After 52 weeks, choice of treatment 
was left to participants and their physicians. Place of residence was recorded during the fi rst 52 weeks of the trial and 
then every 26 weeks for a further 3 years. A secondary outcome of the trial, reported in this study, was nursing home 
placement: an irreversible move from independent accommodation to a residential caring facility. Analyses restricted to 
risk of placement in the fi rst year of follow-up after the patients had completed the double-blind phase of the trial were 
post-hoc. The DOMINO-AD trial is registered with the ISRCTN Registry, number ISRCTN49545035.
Findings Between Feb 11, 2008, and March 5, 2010, 73 (25%) patients were randomly assigned to continue donepezil 
without memantine, 73 (25%) to discontinue donepezil without memantine, 76 (26%) to discontinue donepezil and start 
memantine, and 73 (25%) to continue donepezil and start memantine. 162 (55%) patients underwent nursing home 
placement within 4 years of randomisation, with similar numbers for all groups (36 [49%] in patients who continued 
donepezil without memantine, 42 [58%] who discontinued donepezil without memantine, 41 [54%] who discontinued 
donepezil and started memantine, and 43 [59%] who continued donepezil and started memantine). We noted signifi cant 
(p=0·010) heterogeneity of treatment eff ect over time, with signifi cantly more nursing home placements in the combined 
donepezil discontinuation groups during the fi rst year (hazard ratio 2·09 [95% CI 1·29–3·39]) than in the combined 
donepezil continuation groups, and no diff erence during the next 3 years (0·89 [0·58–1·35]). We noted no eff ect of 
patients starting memantine compared with not starting memantine during the fi rst year (0·92 [0·58–1·45]) or the next 
3 years (1·23 [0·81–1·87]).
Interpretation Withdrawal of donepezil in patients with moderate-to-severe Alzheimer’s disease increased the risk of 
nursing home placement during 12 months of treatment, but made no diff erence during the following 3 years of follow-
up. Decisions to stop or continue donepezil treatment should be informed by potential risks of withdrawal, even if the 
perceived benefi ts of continued treatment are not clear.
Funding Medical Research Council and UK Alzheimer’s Society.
Introduction
Reasons for nursing home placement are complex, 
involving patient and caregiver characteristics, and the 
cultural and social environment. White ethnic origin, 
impairments in cognition and activities of daily living 
(ADL), behavioural problems, and increased age of and 
burden on caregivers all predict nursing home 
placement in Alzheimer’s disease.1 Economic costs of 
dementia increase markedly with disease severity, with 
nursing home placement contributing substantially to 
total support costs of severe dementia. Whether 
cholinesterase inhibitors and memantine can delay the 
point at which patients with Alzheimer’s disease make 
the transition to permanent residential care is 
controversial. AD2000,2 the only randomised, controlled, 
double-blind trial to directly address this question for 
donepezil, was negative. Investigators of observational 
studies following up patients who have participated in 
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double-blind or open trials, or who received open-label 
treatment (with tacrine,3 with donepezil,4 with tacrine, 
donepezil, or rivastigmine,5,6 with galantamine,7 or with 
memantine combined with a cholinesterase inhibitor),8 
have reported positive results. These studies have been 
criticised because they have not used randomisation, 
placebo control, or blinding of treatment allocation.9–12 
The socioeconomic implications of resolution of this 
controversy are clear. Models based on assumptions that 
the drugs can delay placement show large societal and 
health-care cost savings.13
Previously in the Donepezil and Memantine in 
Moderate to Severe Alzheimer’s Disease (DOMINO-AD) 
study,14 we have shown that continued treatment with 
donepezil in patients with moderate-to-severe Alz-
heimer’s disease is associated with cognitive and 
functional benefi ts during 12 months compared with 
tapering and discontinuing. Slight cognitive and 
functional treatment benefi ts in moderate-to-severe 
dementia could be argued to have only a small eff ect on 
the lives of patients and caregivers. Therefore, an 
important secondary objective of our trial was to 
investigate whether continuation of a drug treatment 
that improved dementia symptoms would also delay 
nursing home placement in patients with Alzheimer’s 
disease who had already reached the severity point at 
which independent home living was likely to be 
compromised. Trial participants have completed 4 years 
of double-blind follow-up and, in this report, we explore 
how treatment allocation (to continuation or dis-
continuation of donepezil and to start or not start 
memantine) aff ected subsequent permanent nursing 
home placement.
Methods
Study design and participants
The DOMINO-AD study was a multicentre (15 secondary 
care memory services in England and Scotland), 
randomised, double-blind, placebo-con trolled trial, with 
a two-by-two factorial design.15 Eligible participants met 
standardised criteria16 for probable or possible moderate 
or severe Alzheimer’s disease, had been prescribed 
donepezil continuously for at least 3 months at a dose of 
10 mg for at least the previous 6 weeks, and had a score 
of between 5 and 13 on the Standardised Mini-Mental 
State Examination (SMMSE).17 Each patient’s pre-
scribing clinician was also considering a change in drug 
treatment. Patients were excluded if they had severe or 
unstable medical disorders, were receiving memantine, 
or were deemed unlikely to adhere to the study 
regimens.
Full ethical approval was received from the Scotland A 
Multicentre Research Ethics Committee. Agreement in 
writing to take part in the study was obtained from 
participants if they had capacity to give informed consent, 
and the main caregivers gave written consent for their 
own involvement and assent for their patient’s 
participation. The trial protocol has been published 
previously.15
Randomisation and masking
The fi rst 80 participants were assigned with use of a 
computer-generated unrestricted randomised list of 
assignments prepared by PPJP to maintain allocation 
concealment by introduction of random imbalance 
before the minimisation algorithm commenced. 
Thereafter, participants were randomly assigned to one 
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Evidence before this study
We searched PubMed up to June 25, 2015, for studies of the 
eff ects of dementia drug treatments on nursing home 
placement using the following terms: (“Alzheimer’s 
treatment” AND “nursing home placement”) OR (“Alzheimer’s 
treatment” AND “care home placement”) OR (“cholinesterase 
inhibitor” AND “placement”). We identifi ed a single double-
blind, randomised, controlled trial, fi ndings from which showed 
no eff ect of donepezil treatment on nursing home placement in 
mild-to-moderate Alzheimer’s disease, and 11 open-treatment 
or retrospective analyses, investigators of which reported 
apparent delayed nursing home placement in patients taking 
cholinesterase inhibitor treatment.
Added value of this study
We showed that patients with moderate-to-severe 
Alzheimer’s disease who continued donepezil treatment were 
at reduced risk of nursing home placement during 12 months 
of a randomised, double-blind, placebo-controlled trial. 
Benefi ts were not maintained after 12 months, at which point 
the patients’ treating physicians chose their treatment. 
Although our results should be deemed exploratory because 
nursing home placement was a secondary outcome and 
analysis restricted to the fi rst 12 months of follow-up was not 
prespecifi ed in the analysis plan, they show that, along with 
cognitive and functional benefi ts, continuation of 
cholinesterase inhibitor treatment is associated with 
potential advantages in maintenance of independent home 
living.
Implications of all the available evidence
Because the symptomatic benefi ts associated with 
cholinesterase inhibitor treatment in Alzheimer’s disease are 
slight, physicians might consider stopping treatment because 
of perceived absence of eff ectiveness once patients have 
become moderately to severely aff ected. The evidence suggests 
that withdrawal of cholinesterase inhibitor treatment is 
associated with worse cognitive and functional outcomes and, 
from this study, earlier transfer to a nursing home than without 
withdrawal. Decisions to continue or stop treatment in patients 
with moderate and severe Alzheimer’s disease should be made 
after consideration of these risks. 
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of four treatment groups using randomised 
minimisation:18 continuation of donepezil, with init-
iation of memantine placebo; discontinuation of 
donepezil, with initiation of memantine placebo; dis-
continuation of donepezil and initiation of memantine; 
or continuation of donepezil and initiation of meman-
tine. Treatment assignments were done by the Medical 
Research Council Clinical Trials Unit. Groups were 
stratifi ed according to centre, duration of donepezil 
treatment before entry (3–6 months vs longer than 
6 months), baseline SMMSE score (5–9 vs 10–13), and 
age (younger than 60 years, 60–74 years, or older than 
74 years). Patients, caregivers, clinicians, outcome 
assessors, and investigators were all masked to 
treatment assignment. 
Procedures
Depending on treatment allocation, donepezil was 
continued at 10 mg per day or discontinued after 4 weeks 
of treatment with 5 mg donepezil, and memantine was 
initiated at 20 mg per day. In the Client Service Receipt 
Inventory (CSRI),19 the following are classifi ed as 
nursing home placement: a care home providing 
nursing care, a care home providing personal care, a 
dual-registered home (providing both personal and 
nursing care), an acute psychiatric ward, a general 
medical ward, and a rehabilitation ward. The following 
are classifi ed as non-nursing home placement: an 
owner-occupied house or fl at, a privately rented house 
or fl at, a house or fl at rented from a housing association 
or local authority, sheltered or warden-controlled hous-
ing, or extra care housing. The CSRI captures the 
patient’s usual place of residence since the last 
assessment together with the number of days spent 
living in other locations. If the usual place of residence 
had changed to a nursing home from the previous visit, 
the date of nursing home placement was estimated as 
the number of days lived outside of a nursing home 
since the previous assessment date subtracted from the 
assessment date at which the change was reported. 
After use of the CSRI in the fi rst year, for the following 
3 years, the caregiver was contacted by telephone every 
26 weeks and asked whether the participant was still 
living at home or had moved to live permanently in a 
residential or nursing home, and if such a move had 
occurred, what the date of transition was. The defi nition 
of nursing home placement and the date of transition to 
nursing home placement remained the same through-
out the study, despite the change in the method of data 
collection.
Discontinue donepezil Continue donepezil Total
Add memantine 
placebo
Add memantine Add memantine 
placebo
Add memantine
Randomly allocated patients 73 76 73 73 295
Age at baseline (years) 77·7 (8·0) 76·2 (8·9) 77·2 (7·5) 77·5 (9·0) 77·1 (8·4)
Male sex 26 (36%) 30 (39%) 22 (30%) 24 (33%) 102 (35%)
Ethnic origin
White 71 (97%) 73 (96%) 69 (95%) 67 (92%) 280 (95%)
Black 2 (3%) 2 (3%) 1 (1%) 4 (5%) 9 (3%)
Other 0 1 (1%) 3 (4%) 2 (3%) 6 (2%)
Donepezil treatment before randomisation (months)
3 to <6 3 (4%) 4 (5%) 3 (4%) 4 (5%) 14 (5%)
6 to <12 8 (11%) 4 (5%) 9 (12%) 3 (4%) 24 (8%)
≥12 62 (85%) 68 (89%) 61 (84%) 66 (90%) 257 (87%)
Male carer 36 (49%) 31 (41%) 36 (49%) 34 (47%) 137 (46%)
Carer lives with patient 65 (89%) 58 (76%) 58 (79%) 53 (73%) 234 (79%)
Relationship of carer
Spouse or partner 56 (77%) 49 (64%) 41 (56%) 43 (59%) 189 (64%)
Son or daughter 15 (21%) 18 (24%) 30 (41%) 28 (38%) 91 (31%)
Other relative 0 7 (9%) 1 (1%) 1 (1%) 9 (3%)
Friend or neighbour 0 2 (3%) 0 0 2 (1%)
Paid carer 2 (3%) 0 1 (1%) 1 (1%) 4 (1%)
SMMSE* 9·1 (2·4) 9·2 (2·5) 9·0 (2·8) 9·1 (2·6) 9·1 (2·6)
BADLS† 28·6 (8·9) 27·1 (9·0) 28·2 (9·0) 26·9 (9·8) 27·7 (9·2)
NPI‡ 22·9 (17·0) 23·1 (16·2) 22·3 (16·7) 20·3 (14·4) 22·2 (16·1)
Data are n, mean (SD), or n (%). SMMSE=Standardised Mini-Mental State Examination. BALDS=Bristol Activities of Daily Living Scale. NPI=Neuropsychiatric Inventory. 
*Range 0–30, with higher scores showing better cognitive function. †Range 0–60, with higher scores showing greater functional impairment. ‡Range 0–144, with higher 
scores showing increased behavioural and psychological symptoms. Reproduced from Howard and colleagues14 by permission of the Massachusetts Medical Society. 
Table 1: Baseline characteristics 
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Outcomes
The primary outcomes of the DOMINO-AD trial were 
scores on the SMMSE and caregiver-rated Bristol 
Activities of Daily Living Scale (BADLS).20 Results of 
these outcomes, along with the secondary outcomes of 
neuropsychiatric symptoms, participant quality of life, 
and caregiver psychological distress outcomes during 
completion of the 52 week intervention, have been 
reported previously.14 In this study, nursing home 
placement is reported with use of the CSRI for the 
52 weeks of trial treatment and telephone calls to the 
patients’ caregivers for the following 3 years.
Statistical analysis
The original planned sample size was 800, but this size 
was adjusted to 430 because of reduced SDs for the 
primary outcomes from an interim masked analysis of 
trial data. The trial was designed with an at least 90% 
power for the primary outcomes, but was not powered to 
show diff erences for time to nursing home placement.
Following the prespecifi ed statistical analysis plan, we 
analysed time to nursing home placement using strat-
ifi ed log-rank (using randomisation minimisation factors 
as strata) and Cox proportional hazards regression, with 
patients who died or withdrew from follow-up before 
nursing home placement censored at date of death or 
withdrawal. We tested the assumption of proportional 
hazards using Shoenfeld residuals, with ranking of 
follow-up time. Because we were analysing a secondary 
outcome of the trial, the statistical analysis plan did not 
include any prespecifi ed analyses in the event of non-
proportional hazards, when the log-rank test has reduced 
power to detect diff erences and standard Cox regression 
is inappropriate. Subsequent analyses were not 
prespecifi ed in the analysis plan because the presence of 
non-proportional hazards was not expected. For situations 
with evidence of non-proportional hazards (p<0·05), we 
split follow-up into distinct periods, with hazards 
assumed to be proportional within each period (piecewise 
proportional hazards modelling). We compared 
regression models with diff erent time period splits using 
the Akaike Information Criterion (AIC). We calculated 
probability of nursing home placement by time after 
randomisation from the Kaplan-Meier survivor function, 
with 95% CIs. We calculated diff erences in centiles of 
survival time and probability of nursing home placement 
between groups with 95% bias-corrected bootstrap CIs 
using 1000 bootstrap replications. We calculated the log-
rank statistic for each stratum and tabulated it with event 
rate ratios using methods previously described21 to explore 
the eff ect of stratifi cation.
The protocol and statistical analysis plan prespecifi ed 
that death before nursing home placement would be 
deemed a censoring event in the same way as withdrawal 
or loss from follow-up. However, nursing home place-
ment might have been more likely in patients who died 
than in those who withdrew from follow-up had the 
patients not died or withdrawn. We therefore did two 
additional sensitivity analyses: fi rst, deeming all deaths 
as nursing home placement events at the time of death 
(equivalent to the composite endpoint of death or 
nursing home placement), and second, a competing-
risks analysis22 modelling the subhazard function of 
nursing home placement in the presence of the 
competing risk of death.
We assessed the following patient baseline covariates 
for association with time to nursing home placement in 
the regression model: age; sex; previous duration of 
donepezil treatment; centre; ethnic origin; sex of carer; 
relationship of carer; whether the patient lives with their 
Discontinue donepezil Continue donepezil








Total follow-up time at risk (person-years) 97·0 100·7 121·0 117·8
Number of NHP events 42 (58%) 41 (54%) 36 (49%) 43 (59%)
NHP rate per 10 person-years 4·33 (3·20–5·86) 4·07 (3·00–5·53) 2·98 (2·15–4·13) 3·65 (2·71–4·92)
Centiles of time to NHP (months)
25% 8·9 (2·6–11·1) 9·0 (6·0–12·0) 12·7 (9·5–14·0) 12·8 (8·9–15·2)
50% 16·7 (11·1–26·2) 16·6 (12·0–22·2) 21·9 (14·0–40·9) 20·7 (15·2–30·0)
Probability of NHP by time after randomisation (months; Kaplan-Meier estimates)
6 0·23 (0·15–0·35) 0·15 (0·08–0·26) 0·07 (0·03–0·16) 0·06 (0·02–0·15)
12 0·37 (0·27–0·50) 0·37 (0·26–0·51) 0·21 (0·12–0·33) 0·20 (0·12–0·32)
24 0·61 (0·48–0·73) 0·66 (0·53–0·79) 0·53 (0·40–0·66) 0·53 (0·40–0·67)
36 0·71 (0·58–0·83) 0·69 (0·56–0·81) 0·62 (0·48–0·75) 0·65 (0·53–0·78)
48 0·77 (0·64–0·88) 0·76 (0·63–0·87) 0·69 (0·56–0·2) 0·86 (0·73–0·95)
Deaths before NHP 17 (23%) 12 (16%) 20 (27%) 17 (23%)
Deaths after NHP 4 (5%) 7 (9%) 7 (10%) 8 (11%)
NHP=nursing home placement.
Table 2: Time to NHP and deaths 
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carer; SMMSE, BADLS, Neuropsychiatric Inventory 
(NPI),23 and DEMQOL-proxy scores;24 EuroQol-5D health 
state; and NPI subscales of delusions, hallucinations, 
agitation and aggression, and irritability and lability. We 
deemed covariates to be predictors only if the treatment-
adjusted eff ect was signifi cant at the 5% level in separate 
univariable models.
Additionally, we used parametric models to describe 
how the underlying risk of nursing home placement 
changes with time. We fi tted the following standard 
parametric models to the data: Weibull, generalised γ, 
log-normal, log-logistic, and Gompertz. Flexible 
para metric survival models do not assume an underlying 
log-linear relation with time or hazard and allow a fl exible 
fully parametric modelling approach.25 We compared 
these models with standard parametric models, choosing 
the best fi tting model using the AIC.
The DOMINO-AD trial is registered with the 
International Standard Randomised Controlled Trial 
Number Registry, number ISRCTN49545035.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
Figure 1: Trial profi le
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writing of the report. Pfi zer-Eisai and Lundbeck donated 
drug and placebo supplies, but had no involvement in 
design or conduct of the study or analysis or reporting of 
the data. All authors had full access to all the data in the 
study and the corresponding author had fi nal 
responsibility for the decision to submit for publication. 
Results
Between Feb 11, 2008, and March 5, 2010, 73 (25%) patients 
were randomly assigned to continue donepezil without 
memantine, 73 (25%) to discontinue donepezil without 
memantine, 76 (26%) to discontinue donepezil and start 
memantine, and 73 (25%) to continue donepezil and start 
memantine. The last participant completed follow-up on 
April 28, 2014. Of the 295 patients, 162 (55%) had nursing 
home placement within 4 years of randomisation. Table 1 
summarises the patient baseline characteristics and table 2 
summarises the time to nursing home placement in each 
of the four treatment groups. Figure 1 shows the trial 
profi le.
In the prespecifi ed analysis, we noted evidence of a 
diff erence in time to nursing home placement between 
those discontinuing and continuing donepezil (stratifi ed 
log-rank test p=0·022), although this diff erence was non-
signifi cant in the unstratifi ed analysis (p=0·100). We noted 
no evidence for an interaction (stratifi ed p=0·168; 
unstratifi ed p=0·446) or a benefi t to patients of starting 
memantine (stratifi ed p=0·719; unstratifi ed p=0·628). 
Subsequent analyses therefore consider only the eff ect of 
discontinuation of donepezil. Figure 2 shows the Kaplan-
Meier survival curves of cumulative probability of nursing 
home placement by treatment group. The 25th percentile 
of time to nursing home placement was greater in patients 
continuing (12·7 months [95% CI 10·4–14·0])than in those 
discontinuing (8·9 months [5·5–10·1]) donepezil, with a 
diff erence of 3·8 months (95% CI 1·5–7·0). We noted no 
diff erence in median time to nursing home placement: 
21·9 months (16·9–29·1) versus 16·7 months (12·7–22·1).
Figure 3 shows the log-rank statistics and event rate 
ratio for each stratum and by time period of nursing 
home placement from randomisation, by whether 
patients were allocated to continue or discontinue done-
pezil. We noted clear evidence of non-proportional 
hazards (p=0·01; fi gure 2), showing that the overall 
hazard ratio (HR) of discontinuation compared with 
continuation of donepezil was not an appropriate 
summary measure because the eff ect of discontinuation 
of donepezil changed with time. Kaplan-Meier survival 
curves seemed to separate during the fi rst 12 months and 
were parallel thereafter. Subsequent results are based on 
analyses that were not prespecifi ed in the analysis plan 
because non-proportional hazards were not expected.
Figure 2: Kaplan-Meier curves of cumulative probability of nursing home 
placement by (A) treatment group, (B) continuation versus 
discontinuation of donepezil, and (C) addition of memantine
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A vs C: HR 1·46 (95% CI 0·94–2·29); p=0·060
B vs C: HR 1·40 (95% CI 0·90–2·20); p=0·060
D vs C: HR 1·22 (95% CI 0·78–1·90); p=0·060
HR 1·29 (95% CI 0·95–1·76); p=0·022
HR 1·08 (95% CI 0·79–1·47); p=0·719
Articles
www.thelancet.com/neurology   Vol 14   December 2015 1177
Splitting of follow-up time at only 12 months resulted 
in better model fi t and lower AIC than splits at any 
combination of 6 months, 12 months, and 24 months 
(data not shown). Discontinuation of donepezil more 
than doubled the instantaneous risk of nursing home 
placement during the fi rst year (HR 2·09 [95% CI 
[1·29–3·39]) compared with continuation of donepezil 
(table 3). This benefi t was maintained after 12 months 
because curves remained roughly equidistant (0·89 
[0·58–1·35]). This HR after 12 months should be 
interpreted with caution because of selection bias:26 it is 
estimated from the subgroup of patients without nursing 
Figure 3: Comparison of the eff ect of discontinuation with continuation of donepezil on risk of nursing home placement in each category of randomisation minimisation strata and time 
period from randomisation
Data are n (%)/N or event rate ratio (95% CI). Error bars are 95% CIs. The dashed line shows the estimate of the unstratifi ed event rate ratio. The comparison of the eff ect of memantine is not shown 
because we noted no overall diff erence on event rate, stratifi ed or unstratifi ed. SMMSE=Standardised Mini-Mental State Examination. *Diff erence between observed and expected events within each 
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home placement by 12 months, which included more 
patients who had discontinued than had continued 
donepezil.
Discontinuation of donepezil treatment increased the 
probability of nursing home placement during the fi rst 
6 months from 0·06 to 0·19 (diff erence 0·13 [95% CI 
0·04–0·21]) and during the fi rst 12 months from 0·20 to 
0·37 (0·17 [0·06–0·28]; table 3). This fi nding shows a 
number needed to treat of 5·88 patients for 12 months to 
prevent one nursing home placement. Patients who lived 
with their carers at baseline had a lower instantaneous 
risk of nursing home placement throughout follow-up 
compared with those who did not (HR 0·63 [95% CI 
0·44–0·89]; p=0·013). This eff ect did not diff er by 
treatment group (p=0·48, test for interaction) and no 
other baseline covariates tested were associated with 
nursing home placement (data not shown).
66 (22%) patients died before nursing home placement, 
with a further 26 (9%) deaths reported after nursing 
home placement (table 2). We noted no evidence for 
diff erences in time to death between groups (p=0·816 
stratifi ed; p=0·971 unstratifi ed). In both the analysis of 
the composite endpoint of death or nursing home 
placement and the competing-risks analysis, the results 
were consistent with the analysis described above in 
which death before nursing home placement was a 
censoring event (data not shown). 
None of the standard parametric models provided a 
good fi t for the data, unlike the fl exible parametric 
survival model. The preferred model was a PH(1) model 
with three degrees of freedom for the time-varying 
covariate of donepezil (active vs placebo). Figure 4 shows 
the fi tted hazard and survivor functions from this 
model, revealing how the underlying risk of nursing 
home placement changes with time. The risk of nursing 
home placement in patients discontinuing donepezil is 
high in the fi rst few months, with a peak at around 
6 months and steadily declining thereafter. The risk of 
nursing home placement in patients continuing 
donepezil is lower during the fi rst 12 months than in 
patients discontinuing donepezil, with the peak not 
occurring until after 12 months and steadily declining 
afterwards. The curves for risk of nursing home 
placement were separate during the fi rst 6–12 months, 
with the risk about equal for both groups from 
12 months onwards.
Continue donepezil Discontinue donepezil Diff erence between groups Add memantine placebo Add memantine Diff erence between groups
Randomly allocated 
patients
146 149 ·· 149 146 ··
Overall ·· ··
Time at risk (years) 238·8 197·8 ·· 218·0 218·6 ··
Number of NHP events 79 83 ·· 78 84 ··
NHP rate (per 10 years) 3·31 (2·65 to 4·12) 4·20 (3·38 to 5·20) ·· 3·58 (2·87 to 4·47) 3·84 (3·10 to 4·76) ··
Hazard ratio Reference 1·29 (0·95 to 1·76) ·· Reference 1·08 (0·79 to 1·47) ··
Proportional hazards p=0·010 ·· ·· p=0·068 ·· ··
0–12 months ·· ··
Time at risk (years) 120·5 104·2 ·· 109·8 114·9 ··
Number of NHP events 26 46 ·· 37 35 ··
NHP rate (per 10 years) 2·16 (1·47 to 3·17) 4·42 (3·31 to 5·89) ·· 3·37 (2·44 to 4·65) 3·05 (2·19 to 4·24) ··
Hazard ratio Reference 2·09 (1·29 to 3·39) ·· Reference 0·92 (0·58 to 1·45) ··
12–48 months
Time at risk (years) 118·3 93·6 ·· 108·2 103·7 ··
Number of NHP events 53 37 ·· 41 49 ··
NHP rate (per 10 years) 4·48 (3·42 to 5·86) 3·95 (2·87 to 5·46) ·· 3·79 (2·79 to 5·15) 4·73 (3·57 to 6·25) ··
Hazard ratio Reference 0·89 (0·58 to 1·35) ·· Reference 1·23 (0·81 to 1·87) ··
Centiles of time to NHP (months)
25% 12·7 (10·4 to 14·0) 8·9 (5·5 to 10·1) –3·8 (–7·0 to –1·5) 10·1 (8·9 to 12·6) 11·2 (8·9 to 12·8) 1·1 (–2·7 to 4·2)
50% 21·9 (16·9 to 29·1) 16·7 (12·7 to 22·1) –5·1 (–12·7 to 2·6) 17·5 (14·0 to 26·2) 19·6 (15·1 to 24·1) 2·2 (–5·5 to 9·3)
Probability of NHP by time after randomisation (months; Kaplan-Meier estimates)
6 0·06 (0·03 to 0·12) 0·19 (0·13 to 0·27) 0·13 (0·04 to 0·21) 0·15 (0·10 to 0·22) 0·10 (0·06 to 0·17) –0·05 (–0·12 to 0·03)
12 0·20 (0·14 to 0·28) 0·37 (0·29 to 0·46) 0·17 (0·06 to 0·28) 0·29 (0·22 to 0·38) 0·28 (0·21 to 0·37) –0·01 (–0·12 to 0·10)
24 0·53 (0·43 to 0·62) 0·63 (0·54 to 0·72) 0·11 (–0·02 to 0·23) 0·56 (0·47 to 0·66) 0·59 (0·50 to 0·69) 0·03 (–0·10 to 0·16)
36 0·63 (0·54 to 0·73) 0·69 (0·60 to 0·78) 0·06 (–0·06 to 0·21) 0·66 (0·57 to 0·75) 0·67 (0·58 to 0·76) 0·01 (–0·13 to 0·15)
48 0·77 (0·68 to 0·85) 0·76 (0·67 to 0·84) –0·01 (–0·14 to 0·13) 0·73 (0·63 to 0·82) 0·81 (0·71 to 0·88) 0·08 (–0·06 to 0·20)
The analyses separated into 0–12 months and 12–48 months periods were not preplanned, but were appropriate in the presence of non-proportional hazards. NHP=nursing home placement. 
Table 3: Summary of time to nursing home placement by donepezil group and separately by memantine group
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Discussion
To our knowledge, we are the fi rst to show a signifi cant 
eff ect of dementia drug treatment on nursing home 
placement using data from a randomised, double-blind 
study. Discontinuation of donepezil treatment in patients 
with moderate-to-severe Alzheimer’s disease was assoc-
iated with a doubling of the instantaneous risk of 
placement to nursing homes during 12 months. We noted 
no signifi cant diff erence in the risk of placement at later 
follow-up points, and starting of memantine treatment 
had no eff ect, either singly or in combination with 
donepezil, at any point in the trial. The comparison 
between treatment groups of time to nursing home 
placement was a secondary objective of the DOMINO-AD 
trial for which the study was not designed to have statistical 
power, and the analysis restricted to the fi rst 12 months 
was not prespecifi ed in the statistical analysis plan. These 
results should therefore be deemed exploratory and would 
ideally need to be substantiated in future studies. Restricted 
mean survival time might be a more appropriate treatment 
eff ect measure than is (average) HR in the presence of 
non-proportional hazards.27 However, in view of the 
apparent disadvantages of withdrawal of cholinesterase 
inhibitor treatment,14 data from further double-blind trials 
are unlikely to become available.
Cholinesterase inhibitors are symptomatic treatments 
for Alzheimer’s disease and are not disease modifying. 
How might symptom worsening, associated with 
withdrawal of donepezil, increase risk of nursing home 
placement? Yaff e and colleagues1 showed that impairment 
in ADL was a more important predictor of nursing home 
placement than cognitive impairment. In their study, 
Kaplan-Meier rates for nursing home placement during 
1 year were 24% for patients with a Mini-Mental State 
Examination (MMSE)28 score of 15–20 and 26% for patients 
with a score of less than 15, but 15% for those who were 
ADL independent and 25% for those with one or more 
ADL dependencies.1 Analysis of data from a long-term 
clinical trial showed that, although baseline ADL score 
aff ected risk of and time to nursing home placement, 
decline in ADL most strongly predicted placement.29 
Withdrawal from donepezil treatment in the DOMINO-AD 
trial was associated with a mean 3 point BADLS 
disadvantage during the 12 month intervention period.14 In 
view of the established eff ect of ADL status and loss of 
ADL on risk of nursing home placement,1,29 the ADL 
worsening noted when patients were withdrawn from 
donepezil in the trial most probably represents the 
mechanism for early nursing home placement.
Because nursing home placement is aff ected by social 
and living circumstances, preferences, and values,1 and 
because fi ndings from a previous randomised controlled 
trial by some of the authors of this study (AD2000)2 were 
unambiguously negative, could donepezil treatment 
plausibly aff ect nursing home placement? Three 
important diff erences exist between the AD20002 and 
DOMINO-AD14 trials that might be relevant. First, 
DOMINO-AD examined the eff ects of withdrawal of 
established donepezil treatment,30 whereas AD2000 
investigated the eff ects of treatment being commenced. 
Second, the mean MMSE score of patients entering 
AD2000 was 19 points, and for DOMINO-AD was 9 points. 
The participant populations were therefore very diff erent 
in terms of dementia severity and proximity to the time of 
greatest risk of nursing home placement. Only 9% of 
patients given donepezil and 14% of those given placebo 
in AD2000 moved into a nursing home in the fi rst 
12 months, and nursing home placement could possibly 
have been too rare an event for a treatment eff ect to be 
noted. Third, the magnitude of treatment eff ect on 
cognition and ADL was greater in DOMINO-AD than in 
AD2000. During 2 years, AD2000 participants who 
received donepezil were a mean of 0·8 MMSE points and 
1·0 BADLS points better than were those on placebo,2 
whereas the mean 12 month drug–placebo diff erences for 
donepezil in DOMINO-AD were 1·9 MMSE points and 
3·0 BADLS points.14 Although the AD2000 investigators 
showed no overall eff ect on nursing home placement, 
they did fi nd that BADLS and NPI scores and age were 
strong independent predictors of nursing home placement 
and, using a multivariate model, predicted that a 2–3 point 
improvement in BADLS with donepezil would have 
reduced the proportion of nursing home placement in 
their sample by 10% in the fi rst year.
A limitation of our data is that we did not collect 
information about dementia drug use after the 52 weeks 
of double-blind trial treatment was completed. Participants 
Figure 4: Change in risk of nursing home placement with time
(A) Fitted hazard and (B) cumulative probability of nursing home placement for the fl exible parametric survival 
model. Solid lines show fi tted estimates and the dashed lines in (B) show Kaplan-Meier non-parametric estimates. 
Shaded areas show 95% CIs. This post-hoc analysis shows how the hazard (instantaneous risk) of NHP changes 
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were not routinely unmasked after completion of the trial 
drug treatment and decisions about their subsequent 
treatment were made by their responsible clinician. A 
second limitation relates to our examination of follow-up 
periods. In the prespecifi ed primary analysis, considering 
the whole follow-up period (with use of a stratifi ed log-
rank test), we noted a signifi cant eff ect of continuation of 
donepezil compared with withdrawal and substitution of 
placebo. However, the piecewise modelling we carried out 
thereafter was not a prespecifi ed analysis, so this factor 
should be borne in mind for interpretation of the results. 
Furthermore, withdrawal from the study drug was 
signifi cantly more common in participants assigned to 
discontinue donepezil than in those assigned to continue,14 
which should also be borne in mind. A strength of our 
data was that DOMINO-AD was designed as a pragmatic 
study to answer questions about treatment of typical 
patients with Alzheimer’s disease within 15 secondary 
care memory centres for people with dementia across 
England and Scotland, and the inclusion and exclusion 
criteria were fairly unselective, to both help participant 
recruitment and ensure study generalisability.
The potential economic benefi ts of prevention or delay 
of nursing home placement in patients with Alzheimer’s 
disease are clear:13,31 in the UK, this prevention or delay 
would reduce costs to public expenditure, even if it 
would increase imputed costs of unpaid care, but 
important positive eff ects on patient quality of life would 
also occur. A survey of caregivers showed that patients 
regarded nursing home placement as a major negative 
determinant of quality of life, with more than two-thirds 
rating delay of nursing home placement as “extremely 
important” or “very important” in maintenance of 
quality of life.32 The decrease in quality of life for people 
with dementia associated with nursing home placement, 
along with societal costs of such placements, have driven 
national policy in England to maintain people with 
dementia within their own households for as long as 
possible. Our data suggest that withdrawal of cholin-
esterase inhibitor treatment in moderate-to-severe 
Alzheimer’s disease brings forward the timing of 
nursing home placement during the following 52 weeks, 
but that this eff ect does not operate at later points during 
further 3 year follow-up. This notion is consistent with 
the eff ects of slight sympto matic improvement in 
cognition and function associated with these drugs.
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